Bromocriptine (Bromocriptinum)

Pharmacodynamics Pharmacokinetics Indications Carefully Contraindications Dosing and Administration Side effects
Read on
Clinical and pharmacological group: & nbsp

Dopaminomimetics

Anti-Parkinsonics

Included in the formulation
  • Aberghin®
    pills inwards 
    FARMTSENTR VILAR, ZAO     Russia
  • Bromocriptine
    pills inwards 
    OZONE, LLC     Russia
  • Bromocriptine-KB
    pills inwards 
    KIEVSKY VITAMIN FACTORY, PAO     Ukraine
  • Bromocriptin-Richter
    pills inwards 
    GEDEON RICHTER, OJSC     Hungary
  • Bromergon
    pills inwards 
    Sandoz d.     Slovenia
  • Parlodel®
    pills inwards 
    Meda AB     Sweden
    • АТХ:

    N.04.B.C   Stimulants of dopamine receptors

    N.04.B.C.01   Bromocriptine

    Pharmacodynamics:

    Stimulates dopamine D2receptors in the brain, suppresses physiological lactation and normalizes menstrual function by inhibiting the release of prolactin from the anterior lobe of the pituitary gland and reducing its concentration in the blood. Reduces the severity of Parkinson's symptoms. Helps reduce the concentration of somatotropin in the blood in patients with acromegaly, reduces the severity of the symptoms of depression.

    Pharmacokinetics:

    Absorption - 28% (when taken orally). The connection with plasma proteins is 90-96% (albumins). Biotransformation occurs in the liver (CYP3A3 / 4), the effect of the first passage in the liver. Half-life is biphasic: 4-4.5 hours (alpha-phase) and 15 hours (final). Metabolites of the drug are excreted with bile (95%) and urine (2.5-5.5%).

    Indications:

    Infertility and dysmenorrhea, provoked by increased synthesis of the hormone prolactin; Mr.insufficiency of the luteal phase; hyperprolactinemia; prolactinomas in women and men; suppression of postpartum lactation; pronounced premenstrual syndrome; acromegaly; benign breast diseases and benign nodal and / or cystic changes in the mammary glands; Parkinson's disease and Parkinsonism

    ICD-10

    II.D10-D36.D24   Benign neoplasm of breast

    II.D10-D36.D35   Benign neoplasm of other and unspecified endocrine glands

    II.D37-D48.D44   Neoplasm of uncertain or unknown character of endocrine glands

    IV.E20-E35.E22.0   Acromegaly and pituitary gigantism

    IV.E20-E35.E22.1   Hyperprolactinemia

    VI.G20-G26.G20   Parkinson's disease

    VI.G20-G26.G21.3   Postencephalitic parkinsonism

    XIV.N60-N64.N60.1   Diffuse cystic mastopathy

    XIV.N80-N98.N94.3   Premenstrual tension syndrome

    XIV.N80-N98.N94.6   Dysmenorrhea, unspecified

    XIV.N80-N98.N97   Female infertility

    Contraindications:

    Individual intolerance; ggestosis; violations of blood pressure (hypertension, hypotension); diseases of the cardiovascular system (recently transferred myocardial infarction, heart rhythm disturbances,heart valve disease in history); endogenous psychosis; liver failure.

    Carefully:With Parkinsonism with signs of dementia, pregnancy, breast-feeding (the drug penetrates into the milk), the simultaneous administration of antihypertensive drugs.
    Pregnancy and lactation:

    It is not recommended to use during pregnancy and during breastfeeding. Action category for the fetus by Food and Drug Administration (US Food and Drug Administration) - B.

    Dosing and Administration:

    The dose of the drug is selected individually in each case. Initial dose 1,25-2,5 mg 1-3 times a day, average therapeutic doses - 10-30 mg in day.

    Side effects:

    Digestive system: nausea, vomiting, dry mouth, constipation.

    Cardiovascular system: decrease blood pressure, whitening of the fingers and toes with cooling, rarely - orthostatic hypotension, collapse.

    Nervous system and sensory organs: headache, dizziness, drowsiness, agitation, decreased visual acuity.

    Others: cramps in the calf muscles, swelling of the mucous membranes, nasal congestion.

    Allergic reactions.

    Overdose:

    When an overdose occurs headache, hallucinations, lower blood pressure. Parenteral administration of metoclopramide is necessary.

    Interaction:

    Incompatible with monoamine oxidase inhibitors (increased side effects) and alcohol (disulfiram-like reactions). Buterophenones, haloperidol, risperidone and other antipsychotics reduce the effect of bromocriptine. When taking with antihypertensive drugs, hypotension, phenylpropanolamine and other sympathomimetics increase - there is a risk of hypertension and stroke.

    Clarithromycin, erythromycin, oleandomycin - an increase in the concentration of bromocriptine.

    Levodopa - increased effect (should reduce the dose of levodopa).

    Oral contraceptives - weakening their effect.

    Ritonavir - an increase in the concentration of bromocriptine by 3 times (should reduce the dose of bromocriptine by 50%).

    Special instructions:

    During therapy, control over liver function, kidney function and blood pressure level is recommended.

    With therapy benign formations it is necessary to exclude malignant processes.

    With caution, it is recommended to use the drug for drivers and people,whose work requires increased attention and speed of decision-making.

    Instructions
    Up